Compare Dyne Therapeutics Inc. Common Stock (DYN) vs GFL Environmental Inc. Subordinate voting shares no par value (GFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs GFL Environmental Inc. Subordinate voting shares no par value — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while GFL Environmental Inc. Subordinate voting shares no par value trades at $42.95 (market cap $18.64B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 6.5× Dyne Therapeutics Inc. Common Stock's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and GFL Environmental Inc. Subordinate voting shares no par value for 6 Days on average.
| DYN | GFL | |
|---|---|---|
Market Cap | $2.86B | $18.64B |
Volume | 3,341,579 | 2,514,524 |
Sector | Health | Industrials |
52-Week High | $26.78 | $46.51 |
52-Week Low | $14.60 | $33.54 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $25.61B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
GFL trades at $42.75, up 0.87% today, with a bullish technical signal from moving averages. Recent Q2 2026 earnings missed estimates, but the company raised full-year 2026 guidance. Revenue is projected to grow to $7.0B in 2026, though net income is expected to turn negative. The company recently acquired SECURE Waste Infrastructure and announced a quarterly dividend, signaling financial activity.
Outlook is mixed: strong analyst buy consensus (77.8%) and positive news flow support upside, but negative profit margins and high valuation ratios pose risks. The stock's performance hinges on execution of growth initiatives and margin improvement in a competitive industrial sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →
